Skip to content

Effects of Respiratory Muscle Training on Tongue Corticomotor Excitability

Effects of a Short Bout of Respiratory Muscle Training on Tongue Corticomotor Excitability in Healthy Adults: A Pilot Study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07737015
Acronym
TMS-RMT
Enrollment
20
Registered
2026-07-30
Start date
2024-10-01
Completion date
2024-12-06
Last updated
2026-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adult Participants

Keywords

Transcranial magnetic stimulation, tongue, motor-evoked potentials, respiratory muscle training, corticomotor excitability

Brief summary

The tongue plays a central role in essential oral functions, including swallowing, speech, and upper airway control. Its coordinated interaction with the respiratory system is particularly relevant in clinical conditions such as obstructive sleep apnea and dysphagia. While respiratory muscle training is increasingly used in these contexts, its effects on the neural control of tongue function remain poorly understood. This randomized cross-over pilot study aimed to investigate the acute effects of inspiratory (IMT) and expiratory (EMT) muscle training on tongue corticomotor excitability using transcranial magnetic stimulation. These results will provide novel insight into the neurophysiological mechanisms linking respiratory interventions and oral motor control.

Interventions

DEVICEIMT

An inspiratory threshold loading device set at 50% of the baseline maximal inspiratory pressure (PImax) was used. The training session consisted of five cycles of 20 breaths performed against the device, with a 2-minute rest period between cycles. Each breath consisted of quiet exhalation through the device, followed by a deep and forceful inspiration against the prescribed load.

DEVICEEMT

An expiratory threshold loading device set at 50% of the baseline maximal expiratory pressure (PEmax) was used. The training session consisted of five cycles of 20 breaths performed against the device, with a 2-minute rest period between cycles. Each breath consisted of quiet inhalation through the device, followed by a deep and forceful expiration against the set load.

Sponsors

Université Catholique de Louvain
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* 18 years of age or older * good general health * ability to read and understand the project information

Exclusion criteria

* medical, physical or psychological disorder * metal implants in the head * medications affecting the nervous system * craniofacial abnormalities * neuromuscular or inflammatory diseases * history of epilepsy * presence of pacemaker or implanted medical devices * pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Motor-evoked potentialsMeasured two times: immediately before the training session (baseline) and immediately after completion of the training session (approximately 45 minutes after baseline)The amplitude of tongue-related motor-evoked potentials are assessed using transcranial magnetic stimulation over the tongue motor cortex.

Secondary

MeasureTime frameDescription
Maximum Inspiratory and Expiratory PressureMeasured two times: immediately before the training session (baseline) and immediately after completion of the training session (approximately 45 minutes after baseline)Maximum Inspiratory and Expiratory pressure will be measured via the POWERBreathe device
Tongue elevation peak pressureMeasured two times: immediately before the training session (baseline) and immediately after completion of the training session (approximately 45 minutes after baseline)Tongue peak pressure during elevation movements will be measured via the IOPI device

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 31, 2026